Shanghai – June 10, 2026 – Cooley advised Laekna (HKSE: 2105.HK), a science-driven biotechnology company, on its exclusive license agreement with Vasque Bio for LAE118, a novel drug candidate discovered and developed by Laekna.

Under the agreement, Laekna grants Vasque Bio an exclusive license to develop, manufacture and commercialize LAE118 on a global basis (excluding mainland China, Hong Kong, Macau and Taiwan), among other rights. Laekna will receive an upfront cash payment of $10 million and the right to acquire up to high teen percentage of Vasque Bio’s outstanding common stock or cash payments in lieu of such common stock, and is also eligible to receive up to $517 million in development and sales milestone payments, as well as tiered royalties based on future net sales.

Yiming Liu, Geoffrey Spolyar, Monica Xu, Zack Gong and Lunga Su led the Cooley transaction team advising Laekna.

Christopher Kimball, Andrew Epstein, Zhijing Yu, Yiying Wang, Tonny Yu, Snow Yang and Nick Mu provided invaluable support.

Cooley previously advised Laekna on its clinical collaboration with Eli Lilly and Company in November 2024.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.